Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06227546 | MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer | PHASE2 | ACTIVE NOT_RECRUITING | 9 | — | — | Apr 15, 2024 | May 1, 2026 | Apr 13, 2026 | 1 | United States |
Investigator-Assessed ORR per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions as assessed by CT or magnetic resonance imaging (MRI) scans (with IV contrast unless contraindicated) of the chest, abdomen, and pelvis every 2 cycles (each cycle is a 28 day cycle). Reported as the number of patients with a complete response (CR) or partial response (PR); ORR = CR+PR; CR = Disappearance of all target lesions.Any pathological lymph nodes (whether target ornon-target) must have reduction in short axis to\<10 mm. PR= At least a 30% decrease in the sum ofdiameters of target lesions, taking as reference the baseline sum diameters.
| Arm | Type | Description |
|---|---|---|
| MCG018 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MGC018 | DRUG | Intravenous (IV) Infusion, 2.7 mg/kg on Day 1 of each 28 day cycle |
Inclusion Criteria: 1. Age greater than or equal to 18 years at time of signing Informed consent form (ICF) 2. Ability to comply with the study protocol, in the investigator's judgment. 3. Histologically or cytologically confirmed advanced small cell lung cancer that is not amenable to definitive t...